Skip to content
  • Saturday, 12 September 2026
  • 6:35 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth
Laboratory Automation & Robotics

Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth

Lana Keisha Apr 19, 2026 0

Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…

Read More
Laboratory Automation & Robotics

Eli Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating

Lana Keisha Apr 17, 2026 0

In a landmark announcement on April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), Eli…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Apr 11, 2026 0

Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Apr 2, 2026 0

Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, concluding fiscal year 2025 as…

Read More
Laboratory Automation & Robotics

Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025

Lana Keisha Mar 26, 2026 0

Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, achieving the coveted position of…

Read More

Posts pagination

1 2
Stanford Medicine researchers unlock potential breakthrough in reversing cellular aging by targeting immune system receptorsDoherty Institute Researchers Unveil Groundbreaking Assay Identifying Four STIs and Antibiotic Resistance with Unprecedented Speed and PrecisionBuild an AI-Powered Learning Management System That Actually Trains PeopleDevelopment of an ultra-sensitive human cardiac troponin I sandwich ELISA
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy PorustobartScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ